New Zenith MD&A Posted on SEDAR

No such message found

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

New Zenith MD&A Posted on SEDAR

posted on Sep 27, 2017 03:44PM

Latest Zenith MD&A are available on SEDAR. One particular statement caught my eye regarding the status of the single-agent ZEN-3694 trial:

"Dose escalation has been completed and dose confirmation has completed enrollment and is close to completion."

No further update on the ZEN-3694/enzalutamide combination therapy trial. It is still unclear if they are still in the dose escalation portion to find the maximum tolerated dose, or if they are in the dose expansion phase.

5 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply